Literature DB >> 8780029

Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine.

Y Glinka1, K F Tipton, M B Youdim.   

Abstract

The catecholaminergic neurotoxin 6-hydroxydopamine causes parkinsonian symptoms in animals and it has been proposed that reactive oxygen species and oxidative stress, enhanced by iron, may play a key role in its toxicity. The present results demonstrate that 6-hydroxydopamine reversibly inhibits complex I (NADH dehydrogenase) of brain mitochondrial respiratory chain in isolated mitochondria. 6-Hydroxydopamine itself, rather than its oxidative products, was responsible for the inhibition. Iron (III) did not enhance inhibition but decreased it by stimulating the nonenzyme oxidation of 6-hydroxydopamine. Inhibition was potentiated to some extent by calcium ion. Desferrioxamine protected complex I activity against the inhibition, but it was not due to its chelator or antioxidative properties. Desferrioxamine was also shown to activate NADH dehydrogenase in the absence of 6-hydroxydopamine. Activation of mitochondrial respiration by desferrioxamine may contribute to the enhanced neuron survival in the presence of desferrioxamine in some neurodegenerative conditions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8780029     DOI: 10.1046/j.1471-4159.1996.66052004.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  39 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease.

Authors:  Sofía Sánchez-Iglesias; Pablo Rey; Estefanía Méndez-Alvarez; José Luis Labandeira-García; Ramón Soto-Otero
Journal:  Neurochem Res       Date:  2006-12-12       Impact factor: 3.996

3.  Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis.

Authors:  Keiichirou Morimura; Connie Cheung; Jerrold M Ward; Janardan K Reddy; Frank J Gonzalez
Journal:  Carcinogenesis       Date:  2005-12-24       Impact factor: 4.944

Review 4.  Genetics of iron regulation and the possible role of iron in Parkinson's disease.

Authors:  Shannon L Rhodes; Beate Ritz
Journal:  Neurobiol Dis       Date:  2008-07-11       Impact factor: 5.996

5.  Alterations in the development of rat cerebellum and impaired behavior of juvenile rats after neonatal 6-OHDA treatment.

Authors:  I Djatchkova-Podkletnova; H Alho
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

Review 6.  Interaction between alpha-synuclein and metal ions, still looking for a role in the pathogenesis of Parkinson's disease.

Authors:  Marco Bisaglia; Isabella Tessari; Stefano Mammi; Luigi Bubacco
Journal:  Neuromolecular Med       Date:  2009       Impact factor: 3.843

Review 7.  Mimicking Parkinson's Disease in a Dish: Merits and Pitfalls of the Most Commonly used Dopaminergic In Vitro Models.

Authors:  Fernanda Martins Lopes; Ivi Juliana Bristot; Leonardo Lisbôa da Motta; Richard B Parsons; Fabio Klamt
Journal:  Neuromolecular Med       Date:  2017-07-18       Impact factor: 3.843

8.  Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurotox Res       Date:  2009-07-16       Impact factor: 3.911

9.  Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1.

Authors:  Nadia G Innamorato; Agnieszka Jazwa; Ana I Rojo; Concepción García; Javier Fernández-Ruiz; Anna Grochot-Przeczek; Anna Stachurska; Alicja Jozkowicz; Jozef Dulak; Antonio Cuadrado
Journal:  PLoS One       Date:  2010-07-28       Impact factor: 3.240

10.  Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease.

Authors:  Stina Friling; Maria Bergsland; Susanna Kjellander
Journal:  BMC Neurosci       Date:  2009-12-11       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.